We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clonesequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.
occurrence among FQ-R E. coli isolates of the clonal group ST1193 [2] [3] [4] [5] [6] . Here, we analyze whether, besides H30, any other clonal expansion is evident among FQ-R E. coli isolates collected in the course of a multicenter surveillance study.
METHODS
As part of a multicenter surveillance study, 6349 consecutive clinical E. coli isolates from urine (96.0%), blood (3.5%), or wounds (0.5%) were obtained in 2016-2017. The study involved 9 clinical microbiology laboratories (sites) in 4 geographically dispersed cities, including Seattle, Washington (Kaiser Permanente Washington [KPWA] , Seattle Children's Hospital, and Harborview Medical Center); Los Angeles, California (Keck and Los Angeles County + University of Southern California medical centers); Minneapolis, Minnesota (Veterans Affairs and Hennepin medical centers); and New York, New York (New York University Langone Medical Center and Langone Brooklyn Hospital). Susceptibility to 12 antibiotics, representing 8 drug classes, and production of extended-spectrum β-lactamases (ESBLs) were tested by disk diffusion according to Clinical and Laboratory Standards Institute guidelines [7] , with intermediate isolates designated as resistant. FQ-R isolates were analyzed further for clonal identity by using a single-nucleotide polymorphism (SNP)-based clonotyping test (7-SNP test) [8] and fumC/fimH sequence typing, which identified the isolate's ST-fimH clonal group [9] . Mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC were identified by sequencing. Presence of the fimH64 allele was identified in quantitative polymerase chain reaction (PCR) using a designed fimH64 SNP-specific primer, H64-F2, 5ʹ-GAACGGATAAGCCGTGACT-3ʹ (forward), in combination with previously described primer 488/483-R, 5ʹ-TCT GCGGTTGTGCCGGATAGG-3ʹ (reverse) [8] , which yields a 316-bp PCR product. EnteroBase was used to identify the differences between the ST14 and ST1193 multilocus sequence type (MLST) alleles (https://enterobase.warwick.ac.uk/species/ ecoli).
At each study site, the prevalence of H30 and ST1193 was compared statistically using the likelihood ratio test. To compare current and historic prevalence values for H30 and ST1193, we used urine E. coli isolates from a previously described study done in 2011 at 4 of the present study sites (KPWA, Harborview, Seattle Children's Hospital, and Veterans Affairs) according to the same protocol as used here [10] . Temporal changes in clonal group prevalence among FQ-R E. coli isolates were estimated using multiple logistic regression, with by-site adjustment for either 4 sites (2011 to 2016-2017 analysis) or 8 sites (2016-2017 analysis). Association of FQ-R E. coli isolates with age was estimated using data from the above-described 2011 study and a 2015 study performed at KPWA [10, 11] . A 2-sample Kolmogorov-Smirnov (K-S) test was used to evaluate differences in age distribution for patients with H30 vs ST1193; the binary age cutoff was chosen based on the age with the largest K-S statistic [12] . Associations of clonal background with age group were assessed using a χ 2 test; multiple logistic regression was used to account for possible confounding due to different studies. Resistance prevalence among H30 and ST1193 isolates from 9 sites (2016-2017) was compared using a χ 2 or 2-tailed Fisher exact test, as appropriate.
Statistical analysis was performed using Stata/IC 14.0 software (StataCorp, College Station, Texas).
RESULTS
Of the 6349 total E. coli study isolates, 1314 (20.7%) were FQ-R. The FQ-R isolates represented 45 clonal groups overall (10-28 per site). At each site, the most prevalent clonal group was H30 (per-site mean, 45.4%), and the second most prevalent was ST1193 (per-site mean, 23.2%) ( Table 1) . Although H30 was significantly more prevalent than ST1193 at 7 of 9 sites (P < .05)-including at least 1 per city-at the remaining 2 sites, each in a different city, the prevalence difference between H30 and ST1193 was nonsignificant ( Table 1 ). By contrast, the prevalence of ST1193 increased both Table 1 ). By contrast, during this interval ST1193 exhibited a 7-fold overall prevalence increase, from negligible in 2011 (3.4%) to 23.4% in 2016-2017 (P < .001), and a significant increase at each of the 4 sites (P < .05).
According to the retrospective analysis of 2 previous studies (see Methods) , patients with ST1193 were significantly younger on average than patients with H30 (P = .034). The largest K-S statistic (D = .339) was around age 40, with ST1193 isolated significantly more frequently from patients aged 18-40 years than H30 (P = .002; Table 1 ) or other FQ-R isolates combined (61 of 238 patients [34.5%]; P = .015). With multivariable adjustment by the study, ST1193 remained highly associated with younger age in comparison to H30 (odds ratio, 4.3; P = .007).
Among the present 1306 FQ-R isolates, we compared the frequency of H30 and ST1193 in relation to urine vs blood source. Whereas H30 was 1.5 times more prevalent among blood isolates than urine isolates, ST1193 exhibited an opposite association, being twice as prevalent among urine isolates as blood isolates (Table 1) . (Due to the 2016-2017 study design, clinical source could not be adjusted for age or other patient's conditions.)
As compared with H30 isolates, ST1193 isolates were less frequently resistant to amoxicillin-clavulanate and cefazolin or produced ESBLs, but more frequently were resistant to trimethoprim-sulfamethoxazole and tetracycline (Table 1) . Despite these differences, both clonal groups exhibited a similarly high prevalence of multidrug resistance, a similarly low prevalence of nitrofurantoin resistance, and nearly universal susceptibility to imipenem.
Sequence analysis of gyrA and parC among 102 randomly selected ST1193 isolates revealed QRDR mutations in both genes (S83L and D87N in gyrA, S80I in parC), indicating that, as with H30, FQ resistance within ST1193 is of chromosomal origin. Furthermore, according to the MLST database, ST1193 belongs to the ST14 clonal complex within E. coli phylogroup B2 and, across the 7 MLST loci, differs from ST14 by only 1 SNP (a nonsynonymous g551a mutation in icd, producing a G184D amino acid substitution), indicating that ST1193 is a recent evolutionary derivative of ST14. Members of ST14, in contrast to ST1193, are almost all fluoroquinolone susceptible (data not shown). Furthermore, according to fumC/fimH sequence typing, ST1193 carries fimH allele number 64, which differs from allele number 27 of ST14 by only 1 SNP (c311t, producing a P104L substitution). The designed fimH64-specific PCR test (see Methods) was positive for all 75 randomly selected ST1193 isolates, but negative for 623 randomly selected FQ-susceptible isolates from the current study. Thus, fimH64 could be a highly specific marker for ST1193, a clonal group that might be entirely FQ-R.
DISCUSSION
This multicenter molecular surveillance study of FQ-R E. coli clinical isolates establishes the widespread occurrence of ST1193 across the United States as an important and growing contributor to the FQ-R E. coli population. As there are already reports of ST1193 being isolated in hospitals in Europe and Asia, it is likely to be a pandemic clonal group similar to H30.
The emergence of ST1193 represents the only known large clonal expansion of FQ-R E. coli isolates apart from the global spread of ST131 H30 over the last 2 decades. The rise of ST1193 apparently began more recently than that of H30, and in contrast to the H30 expansion, which appears to have plateaued, could still be ongoing rapidly.
Clinically, ST1193 differs from H30 in targeting younger patients and seeming to have less tendency to be isolated from blood; this, however, requires further investigation. In addition to being FQ-R, ST1193 isolates are often co-resistant to trimethoprim-sulfamethoxazole and tetracycline, but currently (unlike H30) remain susceptible to most β-lactam antibiotics. Discovery of the basis for the global expansion of ST1193 could provide insights into how successful clonal groups of multidrug-resistant E. coli emerge and what interventions could limit their spread.
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